April 7, 2025 11:00 AM EDT

Immunology startup RayThera secures $110M in Series A raise

Ayisha Sharma

News Reporter

RayThera has collected $110 million in a Series A raise to help it advance a preclinical pipeline of small molecule drugs for immunological diseases. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immunology startup RayThera secures $110M in Series A raise

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Stock market melts down over Trump’s tariffs, and biotech's pain keeps growing

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers

Cell and gene therapy CDMO AmplifyBio shuts down over 'scarcity' of funding

GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

‘This is self-inflicted’: Leerink’s David Risinger on the market shock and hits to biopharma

Rhythm touts Phase 3 win for rare obesity drug in people with brain damage

Im­munol­o­gy start­up RayThera se­cures $110M in Se­ries A raise

News Reporter

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Immunology startup RayThera secures $110M in Series A raise